MET and renal cell carcinoma: As frequently observed in other cancers, the upregulation of the c‐Met in renal cell carcinoma (RCC) is associated with the overall survival in the metastatic stage (mRCC) of the disease, and the staging of the receptor expression could improve the patient management (i.e., therapy with c‐Met tyrosine kinase inhibitors).